Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Price Performance

NASDAQ NERV opened at $2.22 on Thursday. Minerva Neurosciences has a 12 month low of $2.03 and a 12 month high of $10.88. The company has a 50-day moving average of $2.25 and a 200-day moving average of $2.50. The company has a market cap of $15.52 million, a P/E ratio of -5.05 and a beta of 0.12.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.